{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-07-11T04:25:23.901261+00:00","company":{"ticker":"GYRE","cik":1124105,"company_name":"GYRE THERAPEUTICS, INC."},"pagination":{"limit":100,"returned":91,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"Catalyst Biosciences, Inc., GNI USA, Inc., GNI Group Ltd., GNI Hong Kong Limited, Shanghai Genomics, Inc., and Continent Pharmaceuticals Inc.","detail":"merger","count":1,"first_seen":"2023-08-31T23:59:59+00:00","last_seen":"2023-08-31T23:59:59+00:00","evidence_fact_ids":[115663]},{"display_name":"Catalyst Biosciences, Inc., GNI USA, Inc., GNI Group Ltd., GNI Hong Kong Limited, Shanghai Genomics, Inc., the Minority Holders, and Continent Pharmaceuticals Inc.","detail":"merger","count":1,"first_seen":"2023-03-30T23:59:59+00:00","last_seen":"2023-03-30T23:59:59+00:00","evidence_fact_ids":[168145]},{"display_name":"Catalyst, GNI Group and GNI HK","detail":"asset_purchase","count":1,"first_seen":"2023-03-30T23:59:59+00:00","last_seen":"2023-03-30T23:59:59+00:00","evidence_fact_ids":[168146]},{"display_name":"Certain executive officers, directors and stockholders of Company and Cullgen","detail":"merger","count":1,"first_seen":"2026-03-02T23:59:59+00:00","last_seen":"2026-03-02T23:59:59+00:00","evidence_fact_ids":[30617]},{"display_name":"Cullgen, Inc.","detail":"merger","count":1,"first_seen":"2026-03-02T23:59:59+00:00","last_seen":"2026-03-02T23:59:59+00:00","evidence_fact_ids":[30615]},{"display_name":"Cullgen, Inc. and certain holders of Cullgen Capital Stock","detail":"other","count":1,"first_seen":"2026-03-02T23:59:59+00:00","last_seen":"2026-03-02T23:59:59+00:00","evidence_fact_ids":[30618]},{"display_name":"Cullgen, Inc. and certain stockholders","detail":"merger","count":1,"first_seen":"2026-03-02T23:59:59+00:00","last_seen":"2026-03-02T23:59:59+00:00","evidence_fact_ids":[30616]},{"display_name":"GC Biopharma Corp.","detail":"asset_purchase","count":1,"first_seen":"2023-03-02T23:59:59+00:00","last_seen":"2023-03-02T23:59:59+00:00","evidence_fact_ids":[174286]},{"display_name":"GNI Group Ltd. and GNI Hong Kong Limited","detail":"asset_purchase","count":1,"first_seen":"2022-12-27T23:59:59+00:00","last_seen":"2022-12-27T23:59:59+00:00","evidence_fact_ids":[188928]},{"display_name":"GNI USA, Inc., GNI Japan, GNI Hong Kong, Shanghai Genomics, Inc., the Minority Holders, and Continent Pharmaceuticals Inc.","detail":"merger","count":1,"first_seen":"2022-12-27T23:59:59+00:00","last_seen":"2022-12-27T23:59:59+00:00","evidence_fact_ids":[188929]}],"ma_counterparty":[{"display_name":"Beijing Continent Pharmaceuticals Co., Ltd","detail":"change_of_control","count":1,"first_seen":"2023-10-30T23:59:59+00:00","last_seen":"2023-10-30T23:59:59+00:00","evidence_fact_ids":[101947]},{"display_name":"Cullgen Inc.","detail":"acquisition","count":1,"first_seen":"2026-05-04T23:59:59+00:00","last_seen":"2026-05-04T23:59:59+00:00","evidence_fact_ids":[23435]},{"display_name":"GC Biopharma Corp.","detail":"disposition","count":1,"first_seen":"2023-03-02T23:59:59+00:00","last_seen":"2023-03-02T23:59:59+00:00","evidence_fact_ids":[174287]},{"display_name":"GNI Group Ltd. and GNI Hong Kong Limited","detail":"acquisition","count":1,"first_seen":"2022-12-27T23:59:59+00:00","last_seen":"2022-12-27T23:59:59+00:00","evidence_fact_ids":[188931]}]},"facts":[{"fact_type":"shareholder_vote","fact_key":"de0c41e50a63c8258b689509a3bf091cf4e1034a","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2026-06-16T10:30:49+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-10","outcome":"passed","proposal_text":"Approval of Conversion of Series B Preferred Stock","proposal_type":"other","results":[{"broker_non_votes":"1,985,197","subject":null,"votes_abstain":"1,285","votes_against":"16,031","votes_for":"70,497,125","votes_withheld":null}]},"claim":"GYRE THERAPEUTICS, INC. shareholders approved Approval of Conversion of Series B Preferred Stock at the 2026-06-10 meeting.","evidence_excerpt":"Proposal 4: Approval of Conversion of Series B Preferred Stock The issuance of shares of the Company’s common stock, par value $0.001 per share, upon conversion of the Company’s Series B Convertible Preferred Stock, par value $0.001 per share, was approved, in accordance with Nasdaq Listing Rule 5635(a), as follows: Votes For Votes Against Abstentions Broker Non-Votes 70,497,125 16,031 1,285 1,985,197","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-26-025324","anchor_url":"https://secwatch.observer/filing/0001140361-26-025324#claim-de0c41e50a63c8258b689509a3bf091cf4e1034a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126025324/0001140361-26-025324-index.htm"},{"fact_type":"shareholder_vote","fact_key":"77e596c84097bceca56b96db5ff84e6ab297af65","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2026-06-16T10:30:49+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-10","outcome":"passed","proposal_text":"Ratification of Independent Auditor","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"416","votes_against":"11,626","votes_for":"72,487,596","votes_withheld":null}]},"claim":"GYRE THERAPEUTICS, INC. shareholders approved Ratification of Independent Auditor at the 2026-06-10 meeting.","evidence_excerpt":"Proposal 3: Ratification of Independent Auditor The appointment of Grant Thornton Zhitong Certified Public Accountants LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 was ratified as follows: Votes For Votes Against Abstentions Broker Non-Votes 72,487,596 11,626 416 0","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-26-025324","anchor_url":"https://secwatch.observer/filing/0001140361-26-025324#claim-77e596c84097bceca56b96db5ff84e6ab297af65","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126025324/0001140361-26-025324-index.htm"},{"fact_type":"shareholder_vote","fact_key":"0234f6310d8e7012f799352fd4b5f84d31f4ccea","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2026-06-16T10:30:49+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-10","outcome":"passed","proposal_text":"Non-Binding Advisory Vote on Executive Compensation","proposal_type":"say_on_pay","results":[{"broker_non_votes":"1,985,197","subject":null,"votes_abstain":"1,160","votes_against":"34,907","votes_for":"70,478,374","votes_withheld":null}]},"claim":"GYRE THERAPEUTICS, INC. shareholders approved Non-Binding Advisory Vote on Executive Compensation at the 2026-06-10 meeting.","evidence_excerpt":"Proposal 2: Non-Binding Advisory Vote on Executive Compensation The compensation of the Company’s named executive officers was approved, on a non-binding, advisory basis, as follows: Votes For Votes Against Abstentions Broker Non-Votes 70,478,374 34,907 1,160 1,985,197","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-26-025324","anchor_url":"https://secwatch.observer/filing/0001140361-26-025324#claim-0234f6310d8e7012f799352fd4b5f84d31f4ccea","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126025324/0001140361-26-025324-index.htm"},{"fact_type":"shareholder_vote","fact_key":"0f82baa48d4596e0f387e068905b7576c3ee433d","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2026-06-16T10:30:49+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-10","outcome":"passed","proposal_text":"Election of Class II Directors","proposal_type":"director_election","results":[{"broker_non_votes":"1,985,197","subject":"David M. Epstein, Ph.D.","votes_abstain":null,"votes_against":null,"votes_for":"70,160,332","votes_withheld":"354,109"},{"broker_non_votes":"1,985,197","subject":"Dan Weng, M.D.","votes_abstain":null,"votes_against":null,"votes_for":"70,483,425","votes_withheld":"31,016"}]},"claim":"GYRE THERAPEUTICS, INC. shareholders approved Election of Class II Directors at the 2026-06-10 meeting.","evidence_excerpt":"The following Class II director nominees were elected to serve until the 2029 Annual Meeting of Stockholders based upon the following votes: Nominee Votes For Votes Withheld Broker Non-Votes •          David M. Epstein, Ph.D. 70,160,332 354,109 1,985,197 •          Dan Weng, M.D. 70,483,425 31,016 1,985,197","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-26-025324","anchor_url":"https://secwatch.observer/filing/0001140361-26-025324#claim-0f82baa48d4596e0f387e068905b7576c3ee433d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126025324/0001140361-26-025324-index.htm"},{"fact_type":"earnings_release","fact_key":"9a33771756927e2ab9471a2598a3c71796e4e75c","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2026-05-07T23:59:59+00:00","payload":{"eps_text":"$(0.10)","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the three months ended March 31, 2026","report_date":"2026-05-07","result_type":"reported_results","revenue_text":"$22.5 million"},"claim":"GYRE THERAPEUTICS, INC. reported the three months ended March 31, 2026 results: revenue $22.5 million, EPS $(0.10). Guidance reaffirmed.","evidence_excerpt":"in such a filing. \n\n--- EX-99.1 (EX-99.1) ---\n\nEX-99.1 Exhibit 99.1 Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update Q1 2026 revenue of $22.5 million; GAAP basic EPS: $(0.10) Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed NDA for F351 (hydronidone) for CHB-associated liver fibrosis submitted to China’s","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-209789","anchor_url":"https://secwatch.observer/filing/0001193125-26-209789#claim-9a33771756927e2ab9471a2598a3c71796e4e75c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000119312526209789/0001193125-26-209789-index.htm"},{"fact_type":"governance_change","fact_key":"3250af831e43eef4643dd16a2bf9f9c47cf3d8f3","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2026-05-04T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":null,"item_codes_triggered":["5.03"],"summary_text":"Filed a Certificate of Designation creating a new series of preferred stock in connection with a merger."},"claim":"GYRE THERAPEUTICS, INC.: Filed a Certificate of Designation creating a new series of preferred stock in connection with a merger.","evidence_excerpt":"The Company has filed with the Secretary of State of the State of Delaware a Certificate of Designation of Preferences, Rights and Limitations of the Company Preferred Stock (the “Certificate of Designation”) in connection with the Merger referenced in Item 1.01 above.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-26-018716","anchor_url":"https://secwatch.observer/filing/0001140361-26-018716#claim-3250af831e43eef4643dd16a2bf9f9c47cf3d8f3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126018716/0001140361-26-018716-index.htm"},{"fact_type":"ma_transaction","fact_key":"6841749b52a7e3f7b6d3ebad252a6e349897ec88","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2026-05-04T23:59:59+00:00","payload":{"action":"acquisition","closing_date":"2026-05-04","consideration_text":"all-stock transaction that valued Cullgen at approximately $300 million","counterparty":"Cullgen Inc.","effective_date":"2026-05-04","item_codes_triggered":["2.01"]},"claim":"GYRE THERAPEUTICS, INC. completed an acquisition involving Cullgen Inc. for all-stock transaction that valued Cullgen at approximately $300 million (closed 2026-05-04).","evidence_excerpt":"Revenue Code of 1986, as\n amended. Under the terms of the Merger Agreement, the Company acquired Cullgen in an all-stock transaction that valued Cullgen at\n approximately $300 million. At the effective time of the Merger (the “Effective Time”), each then outstanding share of Cullgen capital stock (the “Cullgen Capital Stock”), excluding shares of Cullgen","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-26-018716","anchor_url":"https://secwatch.observer/filing/0001140361-26-018716#claim-6841749b52a7e3f7b6d3ebad252a6e349897ec88","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126018716/0001140361-26-018716-index.htm"},{"fact_type":"executive_change","fact_key":"8fa097cf45","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2026-05-04T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"not_disclosed","effective_date":"2026-05-04","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":"Thomas Eastling","successor_named":true},"claim":"Ruoyu Chen resigned as Chief Financial Officer at GYRE THERAPEUTICS, INC..","evidence_excerpt":"Ruoyu Chen, who resigned from her position as Chief Financial Officer on such date.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-26-018716","anchor_url":"https://secwatch.observer/filing/0001140361-26-018716#claim-8fa097cf45","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126018716/0001140361-26-018716-index.htm"},{"fact_type":"executive_change","fact_key":"f45c7cb789","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2026-05-04T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2026-05-04","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":true},"claim":"Thomas Eastling was appointed as Chief Financial Officer at GYRE THERAPEUTICS, INC..","evidence_excerpt":"the Company appointed Thomas Eastling as Chief Financial Officer of the Company, to succeed Ruoyu Chen, who resigned from her position as Chief Financial Officer on such date.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-26-018716","anchor_url":"https://secwatch.observer/filing/0001140361-26-018716#claim-f45c7cb789","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126018716/0001140361-26-018716-index.htm"},{"fact_type":"executive_change","fact_key":"625621074d","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2026-05-04T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2026-05-04","interim":false,"role":"Chief Executive Officer, President, Director","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Ying Luo was appointed as Chief Executive Officer, President, Director at GYRE THERAPEUTICS, INC..","evidence_excerpt":"effective immediately after the Effective Time, the Company appointed Ying Luo, Ph.D. as Chief Executive Officer and President of the Company and to the Board as a Class I director.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-26-018716","anchor_url":"https://secwatch.observer/filing/0001140361-26-018716#claim-625621074d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126018716/0001140361-26-018716-index.htm"},{"fact_type":"executive_change","fact_key":"79fee6d5d0","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2026-05-04T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"not_disclosed","effective_date":"2026-05-04","interim":false,"role":"Director, President","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Songjiang Ma resigned as Director, President at GYRE THERAPEUTICS, INC..","evidence_excerpt":"Thomas Eastling and Songjiang Ma resigned from the board of directors of the Company (the \"Board\") and any respective committee of the Board to which they were members, and Mr. Ma also resigned from his position as President of the Company on such date.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-26-018716","anchor_url":"https://secwatch.observer/filing/0001140361-26-018716#claim-79fee6d5d0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126018716/0001140361-26-018716-index.htm"},{"fact_type":"executive_change","fact_key":"e4a28f749d","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2026-05-04T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"not_disclosed","effective_date":"2026-05-04","interim":false,"role":"Director and Member of Committees","role_category":"director","successor_name":null,"successor_named":false},"claim":"Thomas Eastling resigned as Director and Member of Committees at GYRE THERAPEUTICS, INC..","evidence_excerpt":"Thomas Eastling and Songjiang Ma resigned from the board of directors of the Company (the \"Board\") and any respective committee of the Board to which they were members","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-26-018716","anchor_url":"https://secwatch.observer/filing/0001140361-26-018716#claim-e4a28f749d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126018716/0001140361-26-018716-index.htm"},{"fact_type":"earnings_release","fact_key":"752895226dd3dc3e10ccba5ff2d7d1852d5c1051","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2026-03-12T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the fourth quarter and full year ended December 31, 2025","report_date":"2026-03-12","result_type":"reported_results","revenue_text":"$116.6 million"},"claim":"GYRE THERAPEUTICS, INC. reported the fourth quarter and full year ended December 31, 2025 results: revenue $116.6 million. Guidance reaffirmed.","evidence_excerpt":"Full-year 2025 revenue increased 10% year-over-year to $116.6 million, within revised guidance range Full year 2026 revenue guidance of $100.5 to $111.0 million","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-102700","anchor_url":"https://secwatch.observer/filing/0001193125-26-102700#claim-752895226dd3dc3e10ccba5ff2d7d1852d5c1051","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000119312526102700/0001193125-26-102700-index.htm"},{"fact_type":"governance_change","fact_key":"8e8baf4c3840c7de04c59e376ef88cb09817a7a1","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2026-03-02T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2026-03-02","item_codes_triggered":["5.03"],"summary_text":"Gyre Therapeutics expects to file a Certificate of Designation of Preferences, Rights and Limitations of the Company Preferred Stock in connection with a merger, creating a new class of preferred stock with specific dividend, voting, conversion, and anti-takeover provisions."},"claim":"GYRE THERAPEUTICS, INC.: Gyre Therapeutics expects to file a Certificate of Designation of Preferences, Rights and Limitations of the Company Preferred Stock in connection with a merger, creating a new class of preferred stock with specific dividend, voting, conversion, and anti-takeover provisions (effective 2026-03-02).","evidence_excerpt":"The Company expects to file with the Secretary of State of the State of Delaware a Certificate of Designation of Preferences, Rights and Limitations of the Company Preferred Stock (the \"Certificate of Designation\") in connection with the Merger referenced in Item 1.01 above.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-26-007249","anchor_url":"https://secwatch.observer/filing/0001140361-26-007249#claim-8e8baf4c3840c7de04c59e376ef88cb09817a7a1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126007249/0001140361-26-007249-index.htm"},{"fact_type":"material_agreement","fact_key":"38dc914124f7a35bf2aa06c46e16e0a45cb80913","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2026-03-02T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Registration Rights Agreement","agreement_type":"other","counterparty":"Cullgen, Inc. and certain holders of Cullgen Capital Stock","effective_date":null,"item_codes_triggered":["1.01"],"value_text":"Undisclosed"},"claim":"GYRE THERAPEUTICS, INC. entered into Registration Rights Agreement with Cullgen, Inc. and certain holders of Cullgen Capital Stock valued at Undisclosed.","evidence_excerpt":"In connection with the closing of the Merger, the Company will enter into a Registration Rights Agreement (the “Registration Rights Agreement”) with Cullgen and certain holders of shares of Cullgen Capital Stock signatory thereto (the “Company Holders”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-26-007249","anchor_url":"https://secwatch.observer/filing/0001140361-26-007249#claim-38dc914124f7a35bf2aa06c46e16e0a45cb80913","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126007249/0001140361-26-007249-index.htm"},{"fact_type":"material_agreement","fact_key":"6c037f44dfb6f27bcd3453eee870f58fd5f9895d","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2026-03-02T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Lock-Up Agreements","agreement_type":"merger","counterparty":"Certain executive officers, directors and stockholders of Company and Cullgen","effective_date":"2026-03-02","item_codes_triggered":["1.01"],"value_text":"Undisclosed"},"claim":"GYRE THERAPEUTICS, INC. entered into Lock-Up Agreements with Certain executive officers, directors and stockholders of Company and Cullgen valued at Undisclosed (effective 2026-03-02).","evidence_excerpt":"Concurrently with the execution of the Merger Agreement, certain executive officers, directors and stockholders of the Company and Cullgen have entered into lock-up agreements (the “Lock-Up Agreements”) pursuant to which, subject to specified exceptions, they have agreed not to transfer their shares of Company Common Stock (or shares convertible for Company Common Stock) for (a) with respect to one-third of the shares of Company Common Stock held by them, the 180-day period following the Merger Closing Date, (b) with respect to one-third of the shares of Company Common Stock held by them, the twelve-month period following the Merger Closing Date, and (c) with respect to one-third of the shares of Company Common Stock held by them, the eighteen month period following the Merger Closing Date.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-26-007249","anchor_url":"https://secwatch.observer/filing/0001140361-26-007249#claim-6c037f44dfb6f27bcd3453eee870f58fd5f9895d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126007249/0001140361-26-007249-index.htm"},{"fact_type":"material_agreement","fact_key":"26130acc28db0c00fc4a01141d1686e049f69330","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2026-03-02T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Support Agreements","agreement_type":"merger","counterparty":"Cullgen, Inc. and certain stockholders","effective_date":"2026-03-02","item_codes_triggered":["1.01"],"value_text":"Undisclosed"},"claim":"GYRE THERAPEUTICS, INC. entered into Support Agreements with Cullgen, Inc. and certain stockholders valued at Undisclosed (effective 2026-03-02).","evidence_excerpt":"Concurrently with the execution of the Merger Agreement, (i) certain officers, directors, and stockholders of the Company (solely in their respective capacities as Company stockholders) have entered into support agreements with the Company and Cullgen to vote all of their shares of Company Common Stock in favor of the Conversion Proposal (the “Company Support Agreement”), and (ii) certain officers, directors and stockholders of Cullgen (solely in their respective capacities as Cullgen stockholders) have entered into support agreements with the Company and Cullgen to vote all of their shares of Cullgen Capital Stock in favor of the adoption and approval of the Merger Agreement and the transactions contemplated thereby and against any alternative acquisition proposals (the “ Cullgen Support Agreement” and together with the Company Support Agreement, the “ Support Agreements”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-26-007249","anchor_url":"https://secwatch.observer/filing/0001140361-26-007249#claim-26130acc28db0c00fc4a01141d1686e049f69330","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126007249/0001140361-26-007249-index.htm"},{"fact_type":"material_agreement","fact_key":"a7b51b194e9a66f8c1cc9c85e7d44105b2a6e408","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2026-03-02T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Merger Agreement","agreement_type":"merger","counterparty":"Cullgen, Inc.","effective_date":"2026-03-02","item_codes_triggered":["1.01"],"value_text":"Undisclosed"},"claim":"GYRE THERAPEUTICS, INC. entered into Merger Agreement with Cullgen, Inc. valued at Undisclosed (effective 2026-03-02).","evidence_excerpt":"Each of the Company and Cullgen has agreed to customary representations, warranties and covenants in the Merger Agreement, including, among others, covenants relating to (1) using commercially reasonable efforts to obtain the requisite approval of its stockholders, (2) non-solicitation of alternative acquisition proposals, (3) the conduct of their respective businesses during the period between the date of signing the Merger Agreement and the closing of the Merger, and (4) the Company filing with the U.S. Securities and Exchange Commission (the “SEC”) a proxy statement and other relevant materials relating to the Conversion Proposal (as defined below).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-26-007249","anchor_url":"https://secwatch.observer/filing/0001140361-26-007249#claim-a7b51b194e9a66f8c1cc9c85e7d44105b2a6e408","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126007249/0001140361-26-007249-index.htm"},{"fact_type":"executive_change","fact_key":"da8f4d6f16","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2025-01-06T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-01-05","interim":false,"role":"Class I director and lead independent director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Ping Zhang was appointed as Class I director and lead independent director at GYRE THERAPEUTICS, INC..","evidence_excerpt":"On January 5, 2025, the Board appointed Ping Zhang as a Class I director of the Company. Mr. Zhang was also appointed as the lead independent director of the Board and a member of the Nominating Committee.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-25-000292","anchor_url":"https://secwatch.observer/filing/0001140361-25-000292#claim-da8f4d6f16","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125000292/0001140361-25-000292-index.htm"},{"fact_type":"executive_change","fact_key":"e0d6c3e4ec","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2025-01-06T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-12-31","interim":false,"role":"Chairman","role_category":"chair","successor_name":null,"successor_named":false},"claim":"Ying Luo resigned as Chairman at GYRE THERAPEUTICS, INC..","evidence_excerpt":"On December 31, 2024, Ying Luo, Ph. D. resigned as Chairman and a member of the board of directors (the “Board”) of Gyre Therapeutics, Inc. (the “Company”), as chair and a member of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”) and as Chairman and a member of the board of directors of Gyre Pharmaceuticals Co., Ltd. (the “Gyre Pharmaceuticals Board”), the Company’s majority indirectly owned subsidiary (“Gyre Pharmaceuticals”), effective immediately, due to his need to focus on other responsibilities at GNI Group Ltd.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-25-000292","anchor_url":"https://secwatch.observer/filing/0001140361-25-000292#claim-e0d6c3e4ec","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125000292/0001140361-25-000292-index.htm"},{"fact_type":"executive_change","fact_key":"88ee80470f","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2024-08-08T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-08-06","interim":false,"role":"Class II director","role_category":"director","successor_name":null,"successor_named":false},"claim":"David Epstein was appointed as Class II director at GYRE THERAPEUTICS, INC..","evidence_excerpt":"the Board of Directors (the “Board”) of Gyre Therapeutics, Inc. (the “Company”) appointed David Epstein, Ph.D. as a Class II director to serve until the Company’s 2026 Annual Meeting of Stockholders and until his successor is duly elected and qualified.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-24-036404","anchor_url":"https://secwatch.observer/filing/0001140361-24-036404#claim-88ee80470f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036124036404/0001140361-24-036404-index.htm"},{"fact_type":"executive_change","fact_key":"587c318b22","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2024-07-05T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-06-30","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Nassim Usman resigned as Director at GYRE THERAPEUTICS, INC..","evidence_excerpt":"On June 28, 2024, Nassim Usman, Ph.D. informed the Company that he intended to resign from the Board, effective as of June 30, 2024.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001140361-24-032511","anchor_url":"https://secwatch.observer/filing/0001140361-24-032511#claim-587c318b22","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036124032511/0001140361-24-032511-index.htm"},{"fact_type":"earnings_release","fact_key":"2bdf0b49635398d146ebeefd12b2d97db5bf87e7","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2024-05-09T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the three months ended March 31, 2024","report_date":"2024-05-09","result_type":"reported_results","revenue_text":"$27.2 million"},"claim":"GYRE THERAPEUTICS, INC. reported the three months ended March 31, 2024 results: revenue $27.2 million.","evidence_excerpt":"of the condensed consolidated financial statements. Financial Results for the Quarter Ended March 31, 2024 • Revenues: For the three months ended March 31, 2024, revenues were $27.2 million as a result of Gyre’s indirect controlling interest in Gyre Pharmaceuticals. For the three months ended March 31, 2023, revenues were $24.9 million. The increase was driven by a","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-24-056893","anchor_url":"https://secwatch.observer/filing/0000950170-24-056893#claim-2bdf0b49635398d146ebeefd12b2d97db5bf87e7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000095017024056893/0000950170-24-056893-index.htm"},{"fact_type":"earnings_release","fact_key":"7f79f042a975161bb4fa6ee530c6f3b7fdb504ba","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2024-03-26T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"year ended December 31, 2023","report_date":"2024-03-26","result_type":"reported_results","revenue_text":"$112.1 million"},"claim":"GYRE THERAPEUTICS, INC. reported year ended December 31, 2023 results: revenue $112.1 million.","evidence_excerpt":"inflammation modulators. ETUARY became commercially available in the PRC in 2011 and has been included in the National Reimbursement Drug List since 2017. • Generated sales of $112.1 million in 2023. For the year ended December 31, 2023, Gyre Pharmaceuticals generated $112.1 million in sales of ETUARY, representing an increase of 13% from the previous year. As of","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-24-036135","anchor_url":"https://secwatch.observer/filing/0000950170-24-036135#claim-7f79f042a975161bb4fa6ee530c6f3b7fdb504ba","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000095017024036135/0000950170-24-036135-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"9a14f124a518592cb80615965c59f9c520f65ef6","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2024-03-26T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"regained_compliance","cure_deadline":null,"deficiency_type":"audit_committee","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2024-03-22","notice_type":"compliance_regained","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5605"],"rules_cited_in_text":true},"claim":"GYRE THERAPEUTICS, INC. received a nasdaq compliance regained notice regarding audit committee (rules 5605).","evidence_excerpt":"March 22, 2024, Gyre Therapeutics, Inc. (the “ Company”) received a letter from The Nasdaq Stock Market LLC\n (“Nasdaq”) informing the Company that it had regained compliance with the audit committee composition requirements as set forth in Nasdaq Listing Rule 5605 for continued listing on The Nasdaq Capital Market. As previously disclosed, on January 17, 2024, the Company was notified by Nasdaq that it was not in compliance with Nasdaq Listing Rule 5605 because its Audit Committee was not comprised of at least three “independent directors” (as defined in Nasdaq Listing Rule 5605(a)(2)).\n The C","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-24-015318","anchor_url":"https://secwatch.observer/filing/0001140361-24-015318#claim-9a14f124a518592cb80615965c59f9c520f65ef6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036124015318/0001140361-24-015318-index.htm"},{"fact_type":"executive_change","fact_key":"7ab474ca10","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2024-03-21T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-03-20","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Rodney Nussbaum was appointed as Director at GYRE THERAPEUTICS, INC..","evidence_excerpt":"appointed Rodney Nussbaum as a Class III director to serve until the Company’s 2024 Annual Meeting of Stockholders and until his successor is duly elected and qualified.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-24-014493","anchor_url":"https://secwatch.observer/filing/0001140361-24-014493#claim-7ab474ca10","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036124014493/0001140361-24-014493-index.htm"},{"fact_type":"earnings_release","fact_key":"66cd4700bf18288a55a755f5e56656f672cc1e25","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2024-02-14T23:59:59+00:00","payload":{"eps_text":"169.50","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"9,504","period_text":"FY2023 (January to December)","report_date":"2024-02-14","result_type":"preliminary_results","revenue_text":"26,010"},"claim":"GYRE THERAPEUTICS, INC. reported FY2023 (January to December) results: revenue 26,010, net income 9,504, EPS 169.50. Guidance reaffirmed.","evidence_excerpt":"Profit attributable to owners of the parent Total comprehensive income for the year Million yen % Million yen % Million yen % Million yen % Million yen % Million yen % FY2023 26,010 49.3 13,108 851.3 12,612 - 9,504 - 8,094 - 10,662 - FY2022 17,418 37.3 1,377 (15.2) 767 (30.6) (868) - 388 (63.5) 187 (88.1) Basic earnings per share Diluted earnings per share","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-24-008051","anchor_url":"https://secwatch.observer/filing/0001140361-24-008051#claim-66cd4700bf18288a55a755f5e56656f672cc1e25","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036124008051/0001140361-24-008051-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"6264fc14f080f078aa05d3f9aa2c03f7d368425a","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2024-01-19T23:59:59+00:00","payload":{"company_response":"intends to rely on cure period and recruit new independent director","compliance_status":"deficient","cure_deadline":"2024-07-15","deficiency_type":"audit_committee","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":"audit committee comprised of at least three independent directors","notice_date":"2024-01-17","notice_type":"noncompliance_notice","plan_due_date":null,"raw_rule_text":"Nasdaq Listing Rule 5605","reported_value":null,"rule_numbers":["5605"],"rules_cited_in_text":true},"claim":"GYRE THERAPEUTICS, INC. received a nasdaq noncompliance notice notice regarding audit committee (rules 5605).","evidence_excerpt":"January 17, 2024, the Company received a letter from Nasdaq confirming that t he Company is no longer in compliance with Nasdaq’s audit committee composition requirements as set forth in Nasdaq Listing Rule 5605, which requires that the audit committee of a listed company be comprised of at least\n three “independent directors” (as defined in Nasdaq Listing Rule 5605(a)(2)) . Pursuant to Nasdaq Listing Rule 5605(c)(4), the Company intends to rely on the cure period to\n reestablish compliance with Nasdaq Listing Rule 5605. The cure period is generally defined as until the earlier of the Company’","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-24-002903","anchor_url":"https://secwatch.observer/filing/0001140361-24-002903#claim-6264fc14f080f078aa05d3f9aa2c03f7d368425a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036124002903/0001140361-24-002903-index.htm"},{"fact_type":"executive_change","fact_key":"f3d13950eb","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2024-01-19T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-01-15","interim":false,"role":"Chair of Compensation Committee","role_category":"other","successor_name":"Dr. Han Ying","successor_named":true},"claim":"Dr. Renate Parry was appointed as Chair of Compensation Committee at GYRE THERAPEUTICS, INC..","evidence_excerpt":"Effective as of January 15, 2024, the Board appointed Dr. Renate Parry as Chair of the Board’s Compensation Committee, replacing Dr. Han Ying","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-24-002903","anchor_url":"https://secwatch.observer/filing/0001140361-24-002903#claim-f3d13950eb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036124002903/0001140361-24-002903-index.htm"},{"fact_type":"executive_change","fact_key":"f2beb6bc8e","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2024-01-19T23:59:59+00:00","payload":{"action":"stepped down","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2024-01-15","interim":false,"role":"Member of Audit Committee","role_category":"director","successor_name":null,"successor_named":false},"claim":"Dr. Han Ying changed role as Member of Audit Committee at GYRE THERAPEUTICS, INC..","evidence_excerpt":"On January 15, 2024, Dr. Ying stepped down as a member of the Board’s Audit Committee.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-24-002903","anchor_url":"https://secwatch.observer/filing/0001140361-24-002903#claim-f2beb6bc8e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036124002903/0001140361-24-002903-index.htm"},{"fact_type":"executive_change","fact_key":"0ab6d03b6e","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2024-01-19T23:59:59+00:00","payload":{"action":"stepped down","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2024-01-15","interim":false,"role":"Chair of Compensation Committee","role_category":"other","successor_name":"Dr. Renate Parry","successor_named":true},"claim":"Dr. Han Ying changed role as Chair of Compensation Committee at GYRE THERAPEUTICS, INC..","evidence_excerpt":"Dr. Han Ying, who stepped down as Chair and member of such committee.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-24-002903","anchor_url":"https://secwatch.observer/filing/0001140361-24-002903#claim-0ab6d03b6e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036124002903/0001140361-24-002903-index.htm"},{"fact_type":"executive_change","fact_key":"e3feab7cce","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2024-01-19T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-01-15","interim":false,"role":"Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Dr. Han Ying was appointed as Chief Executive Officer at GYRE THERAPEUTICS, INC..","evidence_excerpt":"On January 15, 2024, the Company entered into an employment agreement with Dr. Ying (the “Employment Agreement”) to serve as the Company’s Chief Executive Officer.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-24-002903","anchor_url":"https://secwatch.observer/filing/0001140361-24-002903#claim-e3feab7cce","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036124002903/0001140361-24-002903-index.htm"},{"fact_type":"executive_change","fact_key":"65f3d08a97","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2023-12-15T23:59:59+00:00","payload":{"action":"retired","action_category":"departure","departure_tone":"retirement","effective_date":"2024-01-15","interim":false,"role":"Chief Executive Officer","role_category":"ceo","successor_name":"Han Ying","successor_named":true},"claim":"Charles Wu retired as Chief Executive Officer at GYRE THERAPEUTICS, INC..","evidence_excerpt":"Dr. Charles Wu, whose employment with the Company will terminate on such date pursuant to his retirement for health reasons.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-23-057889","anchor_url":"https://secwatch.observer/filing/0001140361-23-057889#claim-65f3d08a97","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123057889/0001140361-23-057889-index.htm"},{"fact_type":"executive_change","fact_key":"5e6b14a543","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2023-12-15T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-01-15","interim":false,"role":"Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Han Ying was appointed as Chief Executive Officer at GYRE THERAPEUTICS, INC..","evidence_excerpt":"On December 13, 2023, Gyre Therapeutics, Inc. (the “Company”) appointed Dr. Han Ying as the Company’s Chief Executive Officer, effective January 15, 2024, to succeed Dr. Charles Wu, whose employment with the Company will terminate on such date pursuant to his retirement for health reasons.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-23-057889","anchor_url":"https://secwatch.observer/filing/0001140361-23-057889#claim-5e6b14a543","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123057889/0001140361-23-057889-index.htm"},{"fact_type":"auditor_change","fact_key":"6b109531e42cdcde4a6df078a8783a40910d31bf","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2023-11-02T23:59:59+00:00","payload":{"action":"engagement","auditor_name":"Grant Thornton Zhitong Certified Public Accountants LLP","disagreement_text":null,"effective_date":"2023-11-02","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":null},"claim":"GYRE THERAPEUTICS, INC. engaged Grant Thornton Zhitong Certified Public Accountants LLP as its auditor.","evidence_excerpt":"(b) Engagement of Independent Registered Public Accounting Firm On the Closing Date, the Audit Committee engaged Grant Thornton Zhitong Certified Public Accountants LLP (“Grant Thornton”) as Gyre’s independent\n registered public accounting firm.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-23-051195","anchor_url":"https://secwatch.observer/filing/0001140361-23-051195#claim-6b109531e42cdcde4a6df078a8783a40910d31bf","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123051195/0001140361-23-051195-index.htm"},{"fact_type":"auditor_change","fact_key":"3e63c382657f74a3c9d95031d1df66faa8c5ba46","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2023-11-02T23:59:59+00:00","payload":{"action":"dismissal","auditor_name":"EisnerAmper LLP","disagreement_text":null,"effective_date":"2023-11-02","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":"Grant Thornton Zhitong Certified Public Accountants LLP"},"claim":"GYRE THERAPEUTICS, INC. dismissed EisnerAmper LLP as its auditor.","evidence_excerpt":"(a) Dismissal of Independent Registered Public Accounting Firm Prior to the Closing Date, EisnerAmper LLP (“EisnerAmper”) served as the independent registered public accounting firm of Catalyst. On the Closing Date,\n following the completion of Catalyst’s audit for the year ended December 31, 2022 and the subsequent interim periods through September 30, 2023, which consisted only of the accounts of Catalyst, and the filing of Catalyst’s Annual Report on Form\n 10-K for the year ended December 31, 2022 and Catalyst’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2023, June 30, 2023 and September 30, 2023, the Audit Committee (the “Audit Committee”) of Gyre’s board of directors dismissed\n EisnerAmper as Gyre’s independent registered public accounting firm.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-23-051195","anchor_url":"https://secwatch.observer/filing/0001140361-23-051195#claim-3e63c382657f74a3c9d95031d1df66faa8c5ba46","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123051195/0001140361-23-051195-index.htm"},{"fact_type":"executive_change","fact_key":"d9cb58c1e6","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2023-11-02T23:59:59+00:00","payload":{"action":"ceased to be an officer","action_category":"departure","departure_tone":"routine","effective_date":"2023-10-30","interim":true,"role":"Interim Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Seline Miller departed as Interim Chief Financial Officer at GYRE THERAPEUTICS, INC..","evidence_excerpt":"Seline Miller, Catalyst’s Interim Chief Financial Officer, ceased to be an officer of Gyre","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-23-051195","anchor_url":"https://secwatch.observer/filing/0001140361-23-051195#claim-d9cb58c1e6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123051195/0001140361-23-051195-index.htm"},{"fact_type":"executive_change","fact_key":"3cef9b6d15","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2023-11-02T23:59:59+00:00","payload":{"action":"ceased to be an officer","action_category":"departure","departure_tone":"routine","effective_date":"2023-10-30","interim":false,"role":"President and Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Nassim Usman departed as President and Chief Executive Officer at GYRE THERAPEUTICS, INC..","evidence_excerpt":"Nassim Usman, Ph.D., Catalyst’s President and Chief Executive Officer, ceased to be an officer of Gyre","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-23-051195","anchor_url":"https://secwatch.observer/filing/0001140361-23-051195#claim-3cef9b6d15","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123051195/0001140361-23-051195-index.htm"},{"fact_type":"governance_change","fact_key":"36bd69bcf66dec7a552534c19ddb939f7e8e5c63","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2023-10-30T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2023-10-30","item_codes_triggered":["5.03"],"summary_text":"Amended and restated bylaws to update proxy and DGCL provisions, remove director range requirement, and make other updates"},"claim":"GYRE THERAPEUTICS, INC.: Amended and restated bylaws to update proxy and DGCL provisions, remove director range requirement, and make other updates (effective 2023-10-30).","evidence_excerpt":"On October 30, 2023, in connection with the Transactions and with the new SEC rules regarding universal proxy cards and certain recent amendments to the Delaware General Corporation Law (the “DGCL”), the Board adopted an amendment and restatement of Gyre’s Amended and Restated Bylaws (as so amended and restated, the “Amended and Restated Bylaws”), effective as of such date","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-23-050292","anchor_url":"https://secwatch.observer/filing/0001140361-23-050292#claim-36bd69bcf66dec7a552534c19ddb939f7e8e5c63","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123050292/0001140361-23-050292-index.htm"},{"fact_type":"governance_change","fact_key":"42a290bbc611ea3894963d50b84439979e5a4c91","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2023-10-30T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2023-10-30","item_codes_triggered":["5.03"],"summary_text":"Amendment to Certificate of Designation of Series X Convertible Preferred Stock to increase designated shares and delete certain conversion payment provision"},"claim":"GYRE THERAPEUTICS, INC.: Amendment to Certificate of Designation of Series X Convertible Preferred Stock to increase designated shares and delete certain conversion payment provision (effective 2023-10-30).","evidence_excerpt":"On October 30, 2023, prior to the Closing, Gyre filed an amendment to Certificate of Designation of Preferences, Rights and Limitations of Series X Convertible Preferred Stock (the “Certificate of Designation” and such amendment, the “Amendment to Certificate of Designation”) with the Secretary of State of the State of Delaware in connection with the Private Placement, effective on October 30, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-23-050292","anchor_url":"https://secwatch.observer/filing/0001140361-23-050292#claim-42a290bbc611ea3894963d50b84439979e5a4c91","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123050292/0001140361-23-050292-index.htm"},{"fact_type":"governance_change","fact_key":"59a00ac4c7f54c0ecf2563401ec708a808fbb0c1","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2023-10-30T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2023-10-30","item_codes_triggered":["5.03"],"summary_text":"Certificate of amendment filed to effect Authorized Share Increase, Reverse Stock Split (1-for-15), and Name Change"},"claim":"GYRE THERAPEUTICS, INC.: Certificate of amendment filed to effect Authorized Share Increase, Reverse Stock Split (1-for-15), and Name Change (effective 2023-10-30).","evidence_excerpt":"On October 27, 2023, prior to the Closing, Catalyst filed a certificate of amendment to Catalyst’s Fourth Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware to effect the Authorized Share Increase, the Reverse Stock Split and the Name Change, each with an effective time of 12:01 a.m. Eastern Time on October 30, 2023 (the “Effective Time”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-23-050292","anchor_url":"https://secwatch.observer/filing/0001140361-23-050292#claim-59a00ac4c7f54c0ecf2563401ec708a808fbb0c1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123050292/0001140361-23-050292-index.htm"},{"fact_type":"ma_transaction","fact_key":"bb735b3fae99af2d2222a870dbed34c67ed22b48","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2023-10-30T23:59:59+00:00","payload":{"action":"change_of_control","closing_date":"2023-10-30","consideration_text":"Catalyst acquired an indirect controlling interest in Beijing Continent Pharmaceuticals Co., Ltd (\"BC\") pursuant to the Business Combination Agreement, which in","counterparty":"Beijing Continent Pharmaceuticals Co., Ltd","effective_date":"2023-10-30","item_codes_triggered":["2.01","5.01"]},"claim":"GYRE THERAPEUTICS, INC. underwent a change of control involving Beijing Continent Pharmaceuticals Co., Ltd for Catalyst acquired an indirect controlling interest in Beijing Continent Pharmaceuticals Co., Ltd (\"BC\") pursuant to the Business Combination Agreement, which in (closed 2023-10-30).","evidence_excerpt":"On October 30, 2023 (the \"Closing Date\"), Gyre Therapeutics, Inc. (formerly known as Catalyst Biosciences, Inc.) (prior to the Closing Date, \"Catalyst\" and after the Closing Date, \"Gyre\") consummated the previously announced business combination (the \"Closing\") pursuant to that certain Business Combination Agreement, dated as of December 26, 2022 and as amended on March 29, 2023 and August 30, 2023 (the \"Business Combination Agreement\"), by and among Catalyst, GNI USA, Inc., a Delaware corporation (\"GNI USA\"), GNI Group Ltd., a company incorporated under the laws of Japan with limited liability (\"GNI Group\"), GNI Hong Kong Limited, a company incorporated under the laws of Hong Kong with limited liability (\"GNI HK\"), Shanghai Genomics, Inc., a company organized under the laws of the People's Republic of China (\"Shanghai Genomics\"), the Minority Holders (as defined therein) and Continent Pharmaceuticals Inc., a Cayman Islands company limited by shares (\"CPI\") (such transactions contempla","confidence":0.91,"filing_url":"https://secwatch.observer/filing/0001140361-23-050292","anchor_url":"https://secwatch.observer/filing/0001140361-23-050292#claim-bb735b3fae99af2d2222a870dbed34c67ed22b48","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123050292/0001140361-23-050292-index.htm"},{"fact_type":"executive_change","fact_key":"9cd6fadcd8","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2023-10-30T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-10-30","interim":false,"role":"Chairman of the Board","role_category":"chair","successor_name":null,"successor_named":false},"claim":"Ying Luo was appointed as Chairman of the Board at GYRE THERAPEUTICS, INC..","evidence_excerpt":"Ying Luo, Ph.D. is serving as the Chairman of the Board.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-23-050292","anchor_url":"https://secwatch.observer/filing/0001140361-23-050292#claim-9cd6fadcd8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123050292/0001140361-23-050292-index.htm"},{"fact_type":"executive_change","fact_key":"62a9866aae","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2023-10-30T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-10-30","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Han Ying was appointed as Director at GYRE THERAPEUTICS, INC..","evidence_excerpt":"Han Ying, Ph.D. (as a Class II Director)","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-23-050292","anchor_url":"https://secwatch.observer/filing/0001140361-23-050292#claim-62a9866aae","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123050292/0001140361-23-050292-index.htm"},{"fact_type":"executive_change","fact_key":"85a7d934fc","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2023-10-30T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-10-30","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Charles Wu was appointed as Director at GYRE THERAPEUTICS, INC..","evidence_excerpt":"Charles Wu, Ph.D. (as a Class III Director)","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-23-050292","anchor_url":"https://secwatch.observer/filing/0001140361-23-050292#claim-85a7d934fc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123050292/0001140361-23-050292-index.htm"},{"fact_type":"executive_change","fact_key":"90fe150b2c","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2023-10-30T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-10-30","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Renate Perry was appointed as Director at GYRE THERAPEUTICS, INC..","evidence_excerpt":"Renate Perry, Ph.D. (as a Class III Director)","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-23-050292","anchor_url":"https://secwatch.observer/filing/0001140361-23-050292#claim-90fe150b2c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123050292/0001140361-23-050292-index.htm"},{"fact_type":"executive_change","fact_key":"814f065c3f","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2023-10-30T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-10-30","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Songjiang Ma was appointed as Director at GYRE THERAPEUTICS, INC..","evidence_excerpt":"appointed the following five (5) individuals to the Board: Gordon G. Carmichael, Ph.D. (as a Class I Director), Songjiang Ma (as a Class I Director)","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-23-050292","anchor_url":"https://secwatch.observer/filing/0001140361-23-050292#claim-814f065c3f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123050292/0001140361-23-050292-index.htm"},{"fact_type":"executive_change","fact_key":"84d07fb89d","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2023-10-30T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-10-30","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Gordon G. Carmichael was appointed as Director at GYRE THERAPEUTICS, INC..","evidence_excerpt":"appointed the following five (5) individuals to the Board: Gordon G. Carmichael, Ph.D. (as a Class I Director), Songjiang Ma (as a Class I Director)","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-23-050292","anchor_url":"https://secwatch.observer/filing/0001140361-23-050292#claim-84d07fb89d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123050292/0001140361-23-050292-index.htm"},{"fact_type":"executive_change","fact_key":"8773692fe2","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2023-10-30T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2023-10-30","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Andrea Hunt resigned as Director at GYRE THERAPEUTICS, INC..","evidence_excerpt":"Augustine Lawlor and Andrea Hunt each notified the board of directors of Catalyst of his or her intention to resign from the Board and committees of the Board on which he or she served, effectively immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-23-050292","anchor_url":"https://secwatch.observer/filing/0001140361-23-050292#claim-8773692fe2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123050292/0001140361-23-050292-index.htm"},{"fact_type":"executive_change","fact_key":"3f79c3c11a","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2023-10-30T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2023-10-30","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Augustine Lawlor resigned as Director at GYRE THERAPEUTICS, INC..","evidence_excerpt":"Augustine Lawlor and Andrea Hunt each notified the board of directors of Catalyst of his or her intention to resign from the Board and committees of the Board on which he or she served, effectively immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-23-050292","anchor_url":"https://secwatch.observer/filing/0001140361-23-050292#claim-3f79c3c11a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123050292/0001140361-23-050292-index.htm"},{"fact_type":"shareholder_vote","fact_key":"009649e50bbf750a02dbed1ca816caab50c1e5f5","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2023-08-31T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-08-29","outcome":"passed","proposal_text":"Advisory Vote on the Frequency of Future Advisory Votes on Executive Compensation","proposal_type":"say_on_pay_frequency","results":[{"broker_non_votes":"14,485,801","subject":"1 Year","votes_abstain":"206,480","votes_against":null,"votes_for":"10,326,688","votes_withheld":null},{"broker_non_votes":null,"subject":"2 Years","votes_abstain":null,"votes_against":null,"votes_for":"43,232","votes_withheld":null},{"broker_non_votes":null,"subject":"3 Years","votes_abstain":null,"votes_against":null,"votes_for":"194,114","votes_withheld":null}]},"claim":"GYRE THERAPEUTICS, INC. shareholders approved Advisory Vote on the Frequency of Future Advisory Votes on Executive Compensation at the 2023-08-29 meeting.","evidence_excerpt":"Proposal 10 – Advisory Vote on the Frequency of Future Advisory Votes on Executive Compensation Catalyst’s stockholders voted on the frequency of future advisory votes on executive compensation on a non-binding, advisory basis by the following votes: Votes For 1 Year Votes for 2 Years Votes for 3 Years Abstentions Broker Non-Votes 10,326,688 43,232 194,114 206,480 14,485,801","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-23-042067","anchor_url":"https://secwatch.observer/filing/0001140361-23-042067#claim-009649e50bbf750a02dbed1ca816caab50c1e5f5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123042067/0001140361-23-042067-index.htm"},{"fact_type":"shareholder_vote","fact_key":"2af494f2561290a861d14bfc307a1e67e529fd4d","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2023-08-31T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-08-29","outcome":"passed","proposal_text":"Approval of the Compensation of Catalyst’s Named Executive Officers","proposal_type":"say_on_pay","results":[{"broker_non_votes":"14,485,801","subject":null,"votes_abstain":"130,105","votes_against":"374,990","votes_for":"10,265,419","votes_withheld":null}]},"claim":"GYRE THERAPEUTICS, INC. shareholders approved Approval of the Compensation of Catalyst’s Named Executive Officers at the 2023-08-29 meeting.","evidence_excerpt":"Proposal 9 – Approval of the Compensation of Catalyst’s Named Executive Officers Catalyst’s stockholders approved the compensation of Catalyst’s Named Executive Officers on a non-binding, advisory basis by the following votes: Votes For Votes Against Abstentions Broker Non-Votes 10,265,419 374,990 130,105 14,485,801","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-23-042067","anchor_url":"https://secwatch.observer/filing/0001140361-23-042067#claim-2af494f2561290a861d14bfc307a1e67e529fd4d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123042067/0001140361-23-042067-index.htm"},{"fact_type":"shareholder_vote","fact_key":"9033b530d0134f2d42b99ae75f5f2b3ad171d139","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2023-08-31T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-08-29","outcome":"passed","proposal_text":"Election of two Class II directors","proposal_type":"director_election","results":[{"broker_non_votes":"14,485,801","subject":"Andrea Hunt","votes_abstain":null,"votes_against":null,"votes_for":"10,523,301","votes_withheld":"247,213"},{"broker_non_votes":"14,485,801","subject":"Nassim Usman, Ph.D.","votes_abstain":null,"votes_against":null,"votes_for":"10,536,961","votes_withheld":"233,553"}]},"claim":"GYRE THERAPEUTICS, INC. shareholders approved Election of two Class II directors at the 2023-08-29 meeting.","evidence_excerpt":"Proposal 8 – Election of Directors Catalyst’s stockholders approved the election of two Class II directors to the Board for three year terms or until their respective successors are elected and qualified or until their earlier resignation or removal, by the following votes: Nominee Votes For Votes Withheld Broker Non-Votes Andrea Hunt 10,523,301 247,213 14,485,801 Nassim Usman, Ph.D. 10,536,961 233,553 14,485,801","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-23-042067","anchor_url":"https://secwatch.observer/filing/0001140361-23-042067#claim-9033b530d0134f2d42b99ae75f5f2b3ad171d139","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123042067/0001140361-23-042067-index.htm"},{"fact_type":"shareholder_vote","fact_key":"4ffee239c30c575431f336eb2ca43e43b1c31a70","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2023-08-31T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-08-29","outcome":"failed","proposal_text":"Approval of Stockholder Action by Written Consent","proposal_type":"charter_amendment","results":[{"broker_non_votes":"14,485,801","subject":null,"votes_abstain":"31,697","votes_against":"884,222","votes_for":"9,854,595","votes_withheld":null}]},"claim":"GYRE THERAPEUTICS, INC. shareholders rejected Approval of Stockholder Action by Written Consent at the 2023-08-29 meeting.","evidence_excerpt":"Proposal 7 – Approval of Stockholder Action by Written Consent Catalyst’s stockholders did not approve the adoption of an amendment to Catalyst’s restated certificate of incorporation to allow stockholders to act by written consent, for so long as GNI USA and its affiliates beneficially own 50% or more of the combined voting power of the outstanding shares of Catalyst Common Stock, by the following votes: Votes For Votes Against Abstentions Broker Non-Votes 9,854,595 884,222 31,697 14,485,801","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-23-042067","anchor_url":"https://secwatch.observer/filing/0001140361-23-042067#claim-4ffee239c30c575431f336eb2ca43e43b1c31a70","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123042067/0001140361-23-042067-index.htm"},{"fact_type":"shareholder_vote","fact_key":"26a1012b23d123163ff88486e365ab16cd45cd7a","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2023-08-31T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-08-29","outcome":"passed","proposal_text":"Approval of the Gyre Therapeutics, Inc. 2023 Omnibus Incentive Plan","proposal_type":"equity_plan","results":[{"broker_non_votes":"14,485,801","subject":null,"votes_abstain":"63,979","votes_against":"538,802","votes_for":"10,167,733","votes_withheld":null}]},"claim":"GYRE THERAPEUTICS, INC. shareholders approved Approval of the Gyre Therapeutics, Inc. 2023 Omnibus Incentive Plan at the 2023-08-29 meeting.","evidence_excerpt":"Proposal 6 – Approval of the Gyre Therapeutics, Inc. 2023 Omnibus Incentive Plan Catalyst’s stockholders approved the adoption of the Gyre Therapeutics, Inc. 2023 Omnibus Incentive Plan, by the following votes: Votes For Votes Against Abstentions Broker Non-Votes 10,167,733 538,802 63,979 14,485,801","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-23-042067","anchor_url":"https://secwatch.observer/filing/0001140361-23-042067#claim-26a1012b23d123163ff88486e365ab16cd45cd7a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123042067/0001140361-23-042067-index.htm"},{"fact_type":"shareholder_vote","fact_key":"53874e180eec5c90775008168ed861e832db8818","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2023-08-31T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-08-29","outcome":"failed","proposal_text":"Approval of the Creation a New Class of Non-Voting Common Stock","proposal_type":"charter_amendment","results":[{"broker_non_votes":"14,485,801","subject":null,"votes_abstain":"52,219","votes_against":"1,187,226","votes_for":"9,531,069","votes_withheld":null}]},"claim":"GYRE THERAPEUTICS, INC. shareholders rejected Approval of the Creation a New Class of Non-Voting Common Stock at the 2023-08-29 meeting.","evidence_excerpt":"Proposal 5 – Approval of the Creation a New Class of Non-Voting Common Stock Catalyst’s stockholders did not approve the adoption of an amendment to Catalyst’s restated certificate of incorporation to authorize up to 20,000,000 shares of non-voting common stock, par value $0.001 pers share, by the following votes: Votes For Votes Against Abstentions Broker Non-Votes 9,531,069 1,187,226 52,219 14,485,801","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-23-042067","anchor_url":"https://secwatch.observer/filing/0001140361-23-042067#claim-53874e180eec5c90775008168ed861e832db8818","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123042067/0001140361-23-042067-index.htm"},{"fact_type":"shareholder_vote","fact_key":"c3f8135a6c7b537748636c37e5a19a7d2a37b6a7","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2023-08-31T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-08-29","outcome":"passed","proposal_text":"Approval of the Reverse Stock Split of Catalyst Common Stock","proposal_type":"reverse_split","results":[{"broker_non_votes":null,"subject":"Catalyst Common Stock","votes_abstain":"54,581","votes_against":"823,859","votes_for":"24,377,875","votes_withheld":null},{"broker_non_votes":null,"subject":"Catalyst Series Y Preferred Stock","votes_abstain":"13,645,250","votes_against":"205,964,750","votes_for":"6,094,468,750","votes_withheld":null},{"broker_non_votes":null,"subject":"Catalyst Common Stock + Catalyst Series Y Preferred Stock","votes_abstain":"13,699,831","votes_against":"206,788,609","votes_for":"6,118,846,625","votes_withheld":null}]},"claim":"GYRE THERAPEUTICS, INC. shareholders approved Approval of the Reverse Stock Split of Catalyst Common Stock at the 2023-08-29 meeting.","evidence_excerpt":"Proposal 4 – Approval of the Reverse Stock Split of Catalyst Common Stock Catalyst’s stockholders approved the adoption of an amendment to Catalyst’s restated certificate of incorporation to effect a reverse stock split of Catalyst’s issued common stock by a ratio of not less than 1-for-10 and not more than 1-for-60, such ratio to be determined in the discretion of Board of Directors of Catalyst (the “Board”), by the following votes: Holders Votes For Votes Against Abstentions Catalyst Common Stock 24,377,875 823,859 54,581 Catalyst Series Y Preferred Stock 6,094,468,750 205,964,750 13,645,250 Catalyst Common Stock + Catalyst Series Y Preferred Stock 6,118,846,625 206,788,609 13,699,831","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-23-042067","anchor_url":"https://secwatch.observer/filing/0001140361-23-042067#claim-c3f8135a6c7b537748636c37e5a19a7d2a37b6a7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123042067/0001140361-23-042067-index.htm"},{"fact_type":"shareholder_vote","fact_key":"3730a60d45246b5353bf4577bafb739bbe74bb86","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2023-08-31T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-08-29","outcome":"passed","proposal_text":"Approval of Increasing the Number of Authorized Shares of Catalyst Common Stock","proposal_type":"charter_amendment","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"181,421","votes_against":"719,069","votes_for":"24,355,825","votes_withheld":null}]},"claim":"GYRE THERAPEUTICS, INC. shareholders approved Approval of Increasing the Number of Authorized Shares of Catalyst Common Stock at the 2023-08-29 meeting.","evidence_excerpt":"Proposal 3 – Approval of Increasing the Number of Authorized Shares of Catalyst Common Stock Catalyst’s stockholders approved the adoption of an amendment to Catalyst’s restated certificate of incorporation to increase the number of authorized shares of Catalyst Common Stock from 100,000,000 shares to 400,000,000 shares, by the following votes: Votes For Votes Against Abstentions 24,355,825 719,069 181,421","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-23-042067","anchor_url":"https://secwatch.observer/filing/0001140361-23-042067#claim-3730a60d45246b5353bf4577bafb739bbe74bb86","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123042067/0001140361-23-042067-index.htm"},{"fact_type":"shareholder_vote","fact_key":"1ce9eca2350c65d9a6065fd4cd14e86fa7a12ec7","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2023-08-31T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-08-29","outcome":"passed","proposal_text":"Approval of the Conversion of Catalyst Convertible Preferred Stock into Shares of Catalyst Common Stock","proposal_type":"other","results":[{"broker_non_votes":"14,485,801","subject":null,"votes_abstain":"30,326","votes_against":"214,221","votes_for":"4,259,446","votes_withheld":null}]},"claim":"GYRE THERAPEUTICS, INC. shareholders approved Approval of the Conversion of Catalyst Convertible Preferred Stock into Shares of Catalyst Common Stock at the 2023-08-29 meeting.","evidence_excerpt":"Proposal 2 – Approval of the Conversion of Catalyst Convertible Preferred Stock into Shares of Catalyst Common Stock As previously disclosed in the Proxy Statement, GNI Group and GNI HK, collectively holding 6,266,521 shares of Catalyst Common Stock issued under the Asset Purchase Agreement, dated December 26, 2022 and amended on March 29, 2023 (the “Asset Purchase Agreement”), were not entitled to vote on Proposal No. 2 for purposes of compliance with the listing rules of The Nasdaq Stock Market (“Nasdaq”). After subtracting such 6,266,521 shares of Catalyst Common Stock from the total numbers of shares voted on and voted “for” Proposal No. 2, Catalyst’s stockholders approved the conversion of Catalyst Convertible Preferred Stock into shares of Catalyst Common Stock pursuant to the Asset Purchase Agreement, by the following votes: Votes For Votes Against Abstentions Broker Non-Votes 4,259,446 214,221 30,326 14,485,801","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-23-042067","anchor_url":"https://secwatch.observer/filing/0001140361-23-042067#claim-1ce9eca2350c65d9a6065fd4cd14e86fa7a12ec7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123042067/0001140361-23-042067-index.htm"},{"fact_type":"shareholder_vote","fact_key":"fe42b81d19f008005367bba6958c41fbd7b3aaa4","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2023-08-31T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-08-29","outcome":"passed","proposal_text":"Approval of the Issuance of Shares of Catalyst Common Stock and Catalyst Convertible Preferred Stock","proposal_type":"other","results":[{"broker_non_votes":"14,485,801","subject":null,"votes_abstain":"35,448","votes_against":"226,149","votes_for":"10,508,917","votes_withheld":null}]},"claim":"GYRE THERAPEUTICS, INC. shareholders approved Approval of the Issuance of Shares of Catalyst Common Stock and Catalyst Convertible Preferred Stock at the 2023-08-29 meeting.","evidence_excerpt":"Proposal 1 – Approval of the Issuance of Shares of Catalyst Common Stock and Catalyst Convertible Preferred Stock Catalyst’s stockholders approved the issuance of shares of Catalyst Common Stock and Catalyst Series X Convertible Preferred Stock, par value $0.001 per share (the “Catalyst Convertible Preferred Stock”), each pursuant to the terms of the Business Combination Agreement, by the following votes: Votes For Votes Against Abstentions Broker Non-Votes 10,508,917 226,149 35,448 14,485,801","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-23-042067","anchor_url":"https://secwatch.observer/filing/0001140361-23-042067#claim-fe42b81d19f008005367bba6958c41fbd7b3aaa4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123042067/0001140361-23-042067-index.htm"},{"fact_type":"material_agreement","fact_key":"ad310d251b9b2ee93a256972f421380204a611a7","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2023-08-31T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Business Combination Agreement","agreement_type":"merger","counterparty":"Catalyst Biosciences, Inc., GNI USA, Inc., GNI Group Ltd., GNI Hong Kong Limited, Shanghai Genomics, Inc., and Continent Pharmaceuticals Inc.","effective_date":"2023-08-30","item_codes_triggered":["1.01"],"value_text":null},"claim":"GYRE THERAPEUTICS, INC. amended Business Combination Agreement with Catalyst Biosciences, Inc., GNI USA, Inc., GNI Group Ltd., GNI Hong Kong Limited, Shanghai Genomics, Inc., and Continent Pharmaceuticals Inc. (effective 2023-08-30).","evidence_excerpt":"On August 30, 2023, Catalyst Biosciences, Inc., a Delaware corporation (“Catalyst”), GNI USA, Inc., a Delaware corporation (“GNI USA”), GNI Group Ltd., a company incorporated under the laws of Japan with limited liability (“GNI Group”), GNI Hong Kong Limited, a company incorporated under the laws of Hong Kong with limited liability (“GNI HK”), Shanghai Genomics, Inc., a company organized under the laws of the People’s Republic of China (“Shanghai Genomics”, and collectively with GNI USA, GNI Group and GNI HK, the “Contributors”), and Continent Pharmaceuticals Inc., a Cayman Islands company limited by shares (the “CPI”), entered into a second amendment (the “Second Amendment”) to the previously announced Business Combination Agreement, dated as of December 26, 2022, as amended on March 29, 2023 (the “Business Combination Agreement”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-23-042067","anchor_url":"https://secwatch.observer/filing/0001140361-23-042067#claim-ad310d251b9b2ee93a256972f421380204a611a7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123042067/0001140361-23-042067-index.htm"},{"fact_type":"governance_change","fact_key":"4aa29d34d2fe0d181efa09186d28ece8773598b3","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2023-06-20T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2023-06-20","item_codes_triggered":["5.03"],"summary_text":"Filed a Certificate of Designation for Series Y Preferred Stock, setting forth rights, preferences, and limitations in connection with a Reverse Stock Split amendment to the Certificate of Incorporation."},"claim":"GYRE THERAPEUTICS, INC.: Filed a Certificate of Designation for Series Y Preferred Stock, setting forth rights, preferences, and limitations in connection with a Reverse Stock Split amendment to the Certificate of Incorporation (effective 2023-06-20).","evidence_excerpt":"The Company has filed a certificate of designation with respect to the Series Y Preferred Stock (the “Certificate of Designation”) that sets forth the rights, preferences and limitations of the Series Y Preferred Stock","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-23-030517","anchor_url":"https://secwatch.observer/filing/0001140361-23-030517#claim-4aa29d34d2fe0d181efa09186d28ece8773598b3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123030517/0001140361-23-030517-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"a56b6bc474756f6c951e07ff0e0e161f01082b70","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2023-05-05T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"plan_due","cure_deadline":null,"deficiency_type":"late_filing","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":"timely periodic report filing","notice_date":"2023-05-01","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":"th in Nasdaq Marketplace Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Company was grant","reported_value":null,"rule_numbers":["5550(a)(2)","5550(b)(1)"],"rules_cited_in_text":true},"claim":"GYRE THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding late filing (rules 5550(a)(2), 5550(b)(1)).","evidence_excerpt":"that, because the closing bid price for the Company’s common stock listed on Nasdaq was below $1.00 for 30 consecutive trading days, the Company was not in\n compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Marketplace Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Company was granted 180 calendar days, or until May 1,\n 2023, to regain compliance with the Minimum Bid Price Requirement. On May 2, 2023, the Company was notified by the Listing Qualifications Staff (the “Staff”) of Nasdaq that the Company did n","confidence":0.82,"filing_url":"https://secwatch.observer/filing/0001140361-23-023200","anchor_url":"https://secwatch.observer/filing/0001140361-23-023200#claim-a56b6bc474756f6c951e07ff0e0e161f01082b70","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123023200/0001140361-23-023200-index.htm"},{"fact_type":"material_agreement","fact_key":"481efb283833ac10692ece9c5920beeef178470e","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2023-03-30T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"CVR Agreement Amendment","agreement_type":"other","counterparty":null,"effective_date":"2023-03-29","item_codes_triggered":["1.01"],"value_text":null},"claim":"GYRE THERAPEUTICS, INC. amended CVR Agreement Amendment (effective 2023-03-29).","evidence_excerpt":"On March 29, 2023, Catalyst executed an amendment to Contingent Value Rights Agreement (the “ CVR Agreement Amendment ”) to the previously announced Contingent Value Rights Agreement, dated as of December 26, 2022 (the “ CVR Agreement ”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-23-014819","anchor_url":"https://secwatch.observer/filing/0001140361-23-014819#claim-481efb283833ac10692ece9c5920beeef178470e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123014819/0001140361-23-014819-index.htm"},{"fact_type":"material_agreement","fact_key":"9d5cdc0c3d0b8afb8914110c717574584c8d3fb1","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2023-03-30T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Agreement and Amendment","agreement_type":"asset_purchase","counterparty":"Catalyst, GNI Group and GNI HK","effective_date":"2023-03-29","item_codes_triggered":["1.01"],"value_text":null},"claim":"GYRE THERAPEUTICS, INC. amended Agreement and Amendment with Catalyst, GNI Group and GNI HK (effective 2023-03-29).","evidence_excerpt":"On March 29, 2023, Catalyst, GNI Group and GNI HK entered into an agreement and amendment (the “ Agreement and Amendment ”) to the previously announced Asset Purchase Agreement, dated as of December 26, 2022 (the “ F351 Agreement ”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-23-014819","anchor_url":"https://secwatch.observer/filing/0001140361-23-014819#claim-9d5cdc0c3d0b8afb8914110c717574584c8d3fb1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123014819/0001140361-23-014819-index.htm"},{"fact_type":"material_agreement","fact_key":"a1305bbbda330ada54824f25ecb75201665f765a","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2023-03-30T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"BCA Amendment","agreement_type":"merger","counterparty":"Catalyst Biosciences, Inc., GNI USA, Inc., GNI Group Ltd., GNI Hong Kong Limited, Shanghai Genomics, Inc., the Minority Holders, and Continent Pharmaceuticals Inc.","effective_date":"2023-03-29","item_codes_triggered":["1.01"],"value_text":null},"claim":"GYRE THERAPEUTICS, INC. amended BCA Amendment with Catalyst Biosciences, Inc., GNI USA, Inc., GNI Group Ltd., GNI Hong Kong Limited, Shanghai Genomics, Inc., the Minority Holders, and Continent Pharmaceuticals Inc. (effective 2023-03-29).","evidence_excerpt":"On March 29, 2023, Catalyst Biosciences, Inc., a Delaware corporation (“ Catalyst ”), GNI USA, Inc., a Delaware corporation (“ GNI USA ”), GNI Group Ltd., a company incorporated under the laws of Japan with limited liability (“ GNI Group ”), GNI Hong Kong Limited, a company incorporated under the laws of Hong Kong with limited liability (“ GNI HK ”), Shanghai Genomics, Inc., a company organized under the laws of the People’s Republic of China (“ Shanghai Genomics ”, and collectively with GNI USA, GNI Group and GNI HK, the “ Contributors ,” and each a “ Contributor ”), the individuals (each, a “ Minority Holder ” and collectively, the “ Minority Holders ”) listed on Annex A thereto and Continent Pharmaceuticals Inc., a Cayman Islands company limited by shares (the “ CPI ”), entered into an amendment (the “ BCA Amendment ”) to the previously announced Business Combination Agreement, dated as of December 26, 2022 (the “ Business Combination Agreement ”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-23-014819","anchor_url":"https://secwatch.observer/filing/0001140361-23-014819#claim-a1305bbbda330ada54824f25ecb75201665f765a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123014819/0001140361-23-014819-index.htm"},{"fact_type":"ma_transaction","fact_key":"77cec0d07d2b230f61ba68b8ca1cf064c4e2657e","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2023-03-02T23:59:59+00:00","payload":{"action":"disposition","closing_date":"2023-02-27","consideration_text":"$6 million in cash","counterparty":"GC Biopharma Corp.","effective_date":"2023-02-27","item_codes_triggered":["2.01"]},"claim":"GYRE THERAPEUTICS, INC. completed a disposition involving GC Biopharma Corp. for $6 million in cash (closed 2023-02-27).","evidence_excerpt":"(MarzAA), dalcinonacog alpha (DalcA) and CB-2679d-GT (the “Purchased Assets”). In consideration for the purchase of the Purchased Assets, Buyer will pay Catalyst a total of $6 million in cash, with $1 million payable on closing\n and $5 million retained as a hold-back until twenty-four months after the closing, subject to the satisfaction of post-closing","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-23-009748","anchor_url":"https://secwatch.observer/filing/0001140361-23-009748#claim-77cec0d07d2b230f61ba68b8ca1cf064c4e2657e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123009748/0001140361-23-009748-index.htm"},{"fact_type":"material_agreement","fact_key":"7431ed48de1283d54932d21d93159ac932698e07","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2023-03-02T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Purchase Agreement","agreement_type":"asset_purchase","counterparty":"GC Biopharma Corp.","effective_date":"2023-02-27","item_codes_triggered":["1.01"],"value_text":"$6 million in cash, with $1 million payable on closing and $5 million retained as a hold-back"},"claim":"GYRE THERAPEUTICS, INC. entered into Purchase Agreement with GC Biopharma Corp. valued at $6 million in cash, with $1 million payable on closing and $5 million retained as a hold-back (effective 2023-02-27).","evidence_excerpt":"On February 27, 2023, Catalyst Biosciences, Inc. (“Catalyst”) entered into and closed on an Asset Purchase Agreement (the “Purchase Agreement”) with GC Biopharma Corp. (“Buyer”), pursuant to which Buyer acquired on such date Catalyst’s legacy rare bleeding disorder program, including marzeptacog alpha activated (MarZAA), dalcinonacog alpha (DalcA) and CB-2679d-GT (the “Purchased Assets”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-23-009748","anchor_url":"https://secwatch.observer/filing/0001140361-23-009748#claim-7431ed48de1283d54932d21d93159ac932698e07","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123009748/0001140361-23-009748-index.htm"},{"fact_type":"executive_change","fact_key":"d631ce9f42","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2023-01-19T23:59:59+00:00","payload":{"action":"terminated","action_category":"departure","departure_tone":"termination","effective_date":"2023-01-15","interim":false,"role":"Chief Scientific Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Grant Blouse was terminated as Chief Scientific Officer at GYRE THERAPEUTICS, INC..","evidence_excerpt":"On January 15, 2023, Catalyst Biosciences, Inc. (the “Company’”) terminated Grant Blouse Ph.D. from his position as the Chief Scientific Officer of the Company, effective as of January 15, 2023 (the “Effective Date”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-23-002126","anchor_url":"https://secwatch.observer/filing/0001140361-23-002126#claim-d631ce9f42","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123002126/0001140361-23-002126-index.htm"},{"fact_type":"governance_change","fact_key":"28776d6a44dcce9b568d27d1db4ff8804e3e358a","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2022-12-27T23:59:59+00:00","payload":{"change_type":"other","effective_date":"2022-12-26","item_codes_triggered":["5.03"],"summary_text":"Five directors resigned and two new directors were appointed to the Board, along with committee assignments."},"claim":"GYRE THERAPEUTICS, INC.: Five directors resigned and two new directors were appointed to the Board, along with committee assignments (effective 2022-12-26).","evidence_excerpt":"Resignation of Directors On December 26, 2022, immediately prior to the F351 Effective Time, Errol B. De Souza, Ph.D., Jeanne Jew, Geoffrey Ling, M.D./Ph.D., Sharon Tetlow and Eddie Williams voluntarily resigned from Catalyst’s Board of Directors (the “ Board ”). The resignations were made in connection with the consummation of the transactions contemplated by the F351 Agreement and were not due to any disagreement or dispute relating to Catalyst’s operations, policies or practices. Appointment of Directors In accordance with the F351 Agreement, on December 26, 2022, effective as of the F351 Effective Time, the Board appointed Ying Luo, Ph.D. and Mr. Thomas Eastling to the Board as directors.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-22-046943","anchor_url":"https://secwatch.observer/filing/0001140361-22-046943#claim-28776d6a44dcce9b568d27d1db4ff8804e3e358a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036122046943/0001140361-22-046943-index.htm"},{"fact_type":"ma_transaction","fact_key":"2a9e1294068dc9f8c82f417a1da6be70282e6080","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2022-12-27T23:59:59+00:00","payload":{"action":"acquisition","closing_date":"2022-12-26","consideration_text":"$35,000,000 in shares","counterparty":"GNI Group Ltd. and GNI Hong Kong Limited","effective_date":"2022-12-26","item_codes_triggered":["2.01"]},"claim":"GYRE THERAPEUTICS, INC. completed an acquisition involving GNI Group Ltd. and GNI Hong Kong Limited for $35,000,000 in shares (closed 2022-12-26).","evidence_excerpt":"Under the terms of the F351 Agreement and upon the effective time of the transactions contemplated by the F351 Agreement (the “ F351 Effective Time ”), Catalyst paid the Sellers $35,000,000 in the form of: 6,266,521 shares of Catalyst common stock, par value $0.001 per share (the “ Catalyst Common Stock ”);\n\n and 12,340 shares of Catalyst Series X Convertible","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-22-046943","anchor_url":"https://secwatch.observer/filing/0001140361-22-046943#claim-2a9e1294068dc9f8c82f417a1da6be70282e6080","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036122046943/0001140361-22-046943-index.htm"},{"fact_type":"material_agreement","fact_key":"24a6f4514c5bf73133b7d069256240842f9a1965","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2022-12-27T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Business Combination Agreement","agreement_type":"merger","counterparty":"GNI USA, Inc., GNI Japan, GNI Hong Kong, Shanghai Genomics, Inc., the Minority Holders, and Continent Pharmaceuticals Inc.","effective_date":"2022-12-26","item_codes_triggered":["1.01"],"value_text":null},"claim":"GYRE THERAPEUTICS, INC. entered into Business Combination Agreement with GNI USA, Inc., GNI Japan, GNI Hong Kong, Shanghai Genomics, Inc., the Minority Holders, and Continent Pharmaceuticals Inc. (effective 2022-12-26).","evidence_excerpt":"On December 26, 2022, Catalyst, GNI USA, Inc., a Delaware corporation (“ GNI USA ”), GNI Japan, GNI Hong Kong, Shanghai Genomics, Inc., a company organized under the laws of the People’s Republic of China (“ SG ”, and collectively with GNI USA, GNI Japan and GNI HK, “ Contributors ,” and each a “ Contributor ”), the individuals (each, a “ Minority Holder ” and collectively, the “ Minority Holders ”) listed on Annex A to that certain Business Combination Agreement (the “ Business Combination Agreement ”), and Continent Pharmaceuticals Inc., a Cayman Islands company limited by shares (“ CPI ”), entered into the Business Combination Agreement","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-22-046943","anchor_url":"https://secwatch.observer/filing/0001140361-22-046943#claim-24a6f4514c5bf73133b7d069256240842f9a1965","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036122046943/0001140361-22-046943-index.htm"},{"fact_type":"material_agreement","fact_key":"1fae14c1510f6f286d4e04c17a73e682b1d41558","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2022-12-27T23:59:59+00:00","payload":{"action":"entry","agreement_name":"F351 Agreement","agreement_type":"asset_purchase","counterparty":"GNI Group Ltd. and GNI Hong Kong Limited","effective_date":"2022-12-26","item_codes_triggered":["1.01"],"value_text":"$35,000,000"},"claim":"GYRE THERAPEUTICS, INC. entered into F351 Agreement with GNI Group Ltd. and GNI Hong Kong Limited valued at $35,000,000 (effective 2022-12-26).","evidence_excerpt":"On December 26, 2022, Catalyst Biosciences, Inc., a Delaware corporation (“ Catalyst ”), acquired the F351 Assets (as defined below) from GNI Group Ltd., a company incorporated under the laws of Japan with limited liability (“ GNI Japan ”), and GNI Hong Kong Limited, a company incorporated under the laws of Hong Kong with limited liability (“ GNI Hong Kong ” and, together with GNI Japan, the “ Sellers ”), pursuant to that certain Asset Purchase Agreement, dated December 26 2022 (the “ F351 Agreement ”), by and among Catalyst and the Sellers.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-22-046943","anchor_url":"https://secwatch.observer/filing/0001140361-22-046943#claim-1fae14c1510f6f286d4e04c17a73e682b1d41558","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036122046943/0001140361-22-046943-index.htm"},{"fact_type":"executive_change","fact_key":"f3b2f132ea","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2022-12-27T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-12-26","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Augustine Lawlor was appointed as Director at GYRE THERAPEUTICS, INC..","evidence_excerpt":"The Board appointed Mr. Augustine Lawlor to serve as a Class I director","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-22-046943","anchor_url":"https://secwatch.observer/filing/0001140361-22-046943#claim-f3b2f132ea","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036122046943/0001140361-22-046943-index.htm"},{"fact_type":"executive_change","fact_key":"407d016796","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2022-12-27T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-12-26","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Nassim Usman was appointed as Director at GYRE THERAPEUTICS, INC..","evidence_excerpt":"The Board appointed Nassim Usman, Ph.D. to serve as a Class III director","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-22-046943","anchor_url":"https://secwatch.observer/filing/0001140361-22-046943#claim-407d016796","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036122046943/0001140361-22-046943-index.htm"},{"fact_type":"executive_change","fact_key":"ddbbe89d9c","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2022-12-27T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-12-26","interim":false,"role":"Chair of the Board","role_category":"chair","successor_name":null,"successor_named":false},"claim":"Andrea Hunt was appointed as Chair of the Board at GYRE THERAPEUTICS, INC..","evidence_excerpt":"(i) Ms. Andrea Hunt as Chair","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-22-046943","anchor_url":"https://secwatch.observer/filing/0001140361-22-046943#claim-ddbbe89d9c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036122046943/0001140361-22-046943-index.htm"},{"fact_type":"executive_change","fact_key":"3c3a5f625c","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2022-12-27T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-12-26","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Andrea Hunt was appointed as Director at GYRE THERAPEUTICS, INC..","evidence_excerpt":"The Board also appointed Ms. Andrea Hunt to serve as a Class II director","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-22-046943","anchor_url":"https://secwatch.observer/filing/0001140361-22-046943#claim-3c3a5f625c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036122046943/0001140361-22-046943-index.htm"},{"fact_type":"executive_change","fact_key":"56e2906f15","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2022-12-27T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-12-26","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Thomas Eastling was appointed as Director at GYRE THERAPEUTICS, INC..","evidence_excerpt":"the Board appointed Ying Luo, Ph.D. and Mr. Thomas Eastling to the Board as directors.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-22-046943","anchor_url":"https://secwatch.observer/filing/0001140361-22-046943#claim-56e2906f15","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036122046943/0001140361-22-046943-index.htm"},{"fact_type":"executive_change","fact_key":"1ed03fca70","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2022-12-27T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-12-26","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Ying Luo was appointed as Director at GYRE THERAPEUTICS, INC..","evidence_excerpt":"the Board appointed Ying Luo, Ph.D. and Mr. Thomas Eastling to the Board as directors.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-22-046943","anchor_url":"https://secwatch.observer/filing/0001140361-22-046943#claim-1ed03fca70","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036122046943/0001140361-22-046943-index.htm"},{"fact_type":"executive_change","fact_key":"d7621084f6","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2022-12-27T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2022-12-26","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Eddie Williams resigned as Director at GYRE THERAPEUTICS, INC..","evidence_excerpt":"Errol B. De Souza, Ph.D., Jeanne Jew, Geoffrey Ling, M.D./Ph.D., Sharon Tetlow and Eddie Williams voluntarily resigned from Catalyst’s Board of Directors","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-22-046943","anchor_url":"https://secwatch.observer/filing/0001140361-22-046943#claim-d7621084f6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036122046943/0001140361-22-046943-index.htm"},{"fact_type":"executive_change","fact_key":"b2b74ef3ed","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2022-12-27T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2022-12-26","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Sharon Tetlow resigned as Director at GYRE THERAPEUTICS, INC..","evidence_excerpt":"Errol B. De Souza, Ph.D., Jeanne Jew, Geoffrey Ling, M.D./Ph.D., Sharon Tetlow and Eddie Williams voluntarily resigned from Catalyst’s Board of Directors","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-22-046943","anchor_url":"https://secwatch.observer/filing/0001140361-22-046943#claim-b2b74ef3ed","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036122046943/0001140361-22-046943-index.htm"},{"fact_type":"executive_change","fact_key":"8f4d37ff23","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2022-12-27T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2022-12-26","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Geoffrey Ling resigned as Director at GYRE THERAPEUTICS, INC..","evidence_excerpt":"Errol B. De Souza, Ph.D., Jeanne Jew, Geoffrey Ling, M.D./Ph.D., Sharon Tetlow and Eddie Williams voluntarily resigned from Catalyst’s Board of Directors","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-22-046943","anchor_url":"https://secwatch.observer/filing/0001140361-22-046943#claim-8f4d37ff23","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036122046943/0001140361-22-046943-index.htm"},{"fact_type":"executive_change","fact_key":"b2c0b3ce4e","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2022-12-27T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2022-12-26","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Jeanne Jew resigned as Director at GYRE THERAPEUTICS, INC..","evidence_excerpt":"Errol B. De Souza, Ph.D., Jeanne Jew, Geoffrey Ling, M.D./Ph.D., Sharon Tetlow and Eddie Williams voluntarily resigned from Catalyst’s Board of Directors","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-22-046943","anchor_url":"https://secwatch.observer/filing/0001140361-22-046943#claim-b2c0b3ce4e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036122046943/0001140361-22-046943-index.htm"},{"fact_type":"executive_change","fact_key":"b29b5d119a","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2022-12-27T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2022-12-26","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Errol B. De Souza resigned as Director at GYRE THERAPEUTICS, INC..","evidence_excerpt":"Errol B. De Souza, Ph.D., Jeanne Jew, Geoffrey Ling, M.D./Ph.D., Sharon Tetlow and Eddie Williams voluntarily resigned from Catalyst’s Board of Directors","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-22-046943","anchor_url":"https://secwatch.observer/filing/0001140361-22-046943#claim-b29b5d119a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036122046943/0001140361-22-046943-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"13abcc715546d0767562e67b79de218aa69f3a2b","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2022-11-04T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"hearing_requested","cure_deadline":null,"deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":"$1.00 per share","notice_date":"2022-11-02","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":"th in Nasdaq Marketplace Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). In accordance with Na","reported_value":null,"rule_numbers":["5550(a)(2)","5810(c)(3)(A)"],"rules_cited_in_text":true},"claim":"GYRE THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).","evidence_excerpt":"November 2, 2022, Catalyst Biosciences, Inc., a Delaware Corporation (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department of the\n Nasdaq Stock Market (“Nasdaq”) informing the Company that because the closing bid price for the Company’s common stock listed on Nasdaq was below $1.00 for 30 consecutive trading days, the Company is not in compliance with the minimum bid price\n requirement for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Marketplace Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). In accordance with Nasdaq Marke","confidence":0.82,"filing_url":"https://secwatch.observer/filing/0001140361-22-040002","anchor_url":"https://secwatch.observer/filing/0001140361-22-040002#claim-13abcc715546d0767562e67b79de218aa69f3a2b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036122040002/0001140361-22-040002-index.htm"},{"fact_type":"executive_change","fact_key":"b0555312cb","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2021-10-13T23:59:59+00:00","payload":{"action":"promoted","action_category":"role_change","departure_tone":"not_applicable","effective_date":null,"interim":true,"role":"Senior Vice President, Finance and interim Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Seline Miller changed role as Senior Vice President, Finance and interim Chief Financial Officer at GYRE THERAPEUTICS, INC..","evidence_excerpt":"Seline Miller, the Company’s Controller, was promoted to Senior Vice President, Finance and will serve as the Company’s interim Chief Financial Officer and interim Principal Accounting Officer.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-21-297901","anchor_url":"https://secwatch.observer/filing/0001193125-21-297901#claim-b0555312cb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000119312521297901/0001193125-21-297901-index.htm"},{"fact_type":"executive_change","fact_key":"451c360b87","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2021-10-13T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2021-10-29","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":"Seline Miller","successor_named":true},"claim":"Clinton Musil resigned as Chief Financial Officer at GYRE THERAPEUTICS, INC..","evidence_excerpt":"On October 7, 2021, Clinton Musil, Chief Financial Officer of Catalyst Biosciences, Inc. (the “Company”), notified the Company of his decision to resign for personal reasons.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-21-297901","anchor_url":"https://secwatch.observer/filing/0001193125-21-297901#claim-451c360b87","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000119312521297901/0001193125-21-297901-index.htm"},{"fact_type":"executive_change","fact_key":"f5a3eab48b","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2021-09-08T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2021-09-09","interim":false,"role":"Class III director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Jeanne Y. Jew was appointed as Class III director at GYRE THERAPEUTICS, INC..","evidence_excerpt":"On September 8, 2021, Catalyst Biosciences, Inc. (“Catalyst”) announced that the Board of Directors of Catalyst (the “Board”), has appointed, effective as of September 9, 2021 (the “Effective Date”), Ms. Jeanne Y. Jew as a Class III director of Catalyst with a term to expire at the 2024 Annual Meeting of Stockholders.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-21-267331","anchor_url":"https://secwatch.observer/filing/0001193125-21-267331#claim-f5a3eab48b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000119312521267331/0001193125-21-267331-index.htm"},{"fact_type":"executive_change","fact_key":"a22c63a29c","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2021-08-16T23:59:59+00:00","payload":{"action":"retired","action_category":"departure","departure_tone":"retirement","effective_date":"2021-08-15","interim":false,"role":"Chief Medical Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Howard Levy retired as Chief Medical Officer at GYRE THERAPEUTICS, INC..","evidence_excerpt":"Howard Levy, M.B.B.Ch, Ph.D., M.M.M. its Chief Medical Officer plans to retire effective August 15, 2021","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-21-247691","anchor_url":"https://secwatch.observer/filing/0001193125-21-247691#claim-a22c63a29c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000119312521247691/0001193125-21-247691-index.htm"},{"fact_type":"executive_change","fact_key":"e0b9f67487","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2021-07-15T23:59:59+00:00","payload":{"action":"retired","action_category":"departure","departure_tone":"retirement","effective_date":"2021-08-15","interim":false,"role":"Chief Medical Officer","role_category":"other","successor_name":null,"successor_named":false},"claim":"Howard Levy retired as Chief Medical Officer at GYRE THERAPEUTICS, INC..","evidence_excerpt":"On July 14, 2021, the Company announced that Howard Levy, the Company’s Chief Medical Officer, plans to retire from his position.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-21-216469","anchor_url":"https://secwatch.observer/filing/0001193125-21-216469#claim-e0b9f67487","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000119312521216469/0001193125-21-216469-index.htm"},{"fact_type":"executive_change","fact_key":"8334aeb829","cik":1124105,"ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2021-07-15T23:59:59+00:00","payload":{"action":"promoted","action_category":"role_change","departure_tone":"not_applicable","effective_date":null,"interim":false,"role":"Chief Scientific Officer","role_category":"other","successor_name":null,"successor_named":false},"claim":"Grant Blouse changed role as Chief Scientific Officer at GYRE THERAPEUTICS, INC..","evidence_excerpt":"On July 14, 2021, Catalyst Biosciences, Inc. (the “Company”) announced that Grant Blouse has been promoted to Chief Scientific Officer of the Company.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-21-216469","anchor_url":"https://secwatch.observer/filing/0001193125-21-216469#claim-8334aeb829","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1124105/000119312521216469/0001193125-21-216469-index.htm"}]}